Brucellosis is a zoonotic disease which is showing a rising trend. This should be an integral differential in every clinician’s minds when presented with a case of pyrexia of unknown origin. We report a case of brucellosis with no complications, to reiterate the need for prevention rather than cure and identifying high risk cases demonstrating therapeutic failure. Treatment therapies and duration vary amongst pregnant and individuals with complications however monotherapy regimens are not accepted. Emphasis on patient education and prevention would be the best approach for disease control. Screening contacts of an index case and offering post exposure prophylaxis should be incorporated in to the physician’s treatment plan.

Keywords: Zoonotic, Brucellosis, antibiotic resistance, monotherapy, screening.

1. Bosilkovski M, Dimzova M, Grozdanovski K. Natural history of brucellosis in an endemic region in different time periods. Acta Clin Croat 2009.
2. Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 2002.
3. Pappas G, Panagopoulou P, Christou L, Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006.
4. Agasthya AS, Isloor S, Prabhudas K. Brucellosis in high risk group individuals. Indian J Med Microbiol. 2007 Jan.
5. Mantur BG, Amarnath SK. Brucellosis in India – a review. J Biosci. 2008
6. Poulou A, Markou F, Xipolitos I, Skandalakis PN. A rare case of Brucella melitensis infection in an obstetrician during the delivery of a transplacentally infected infant. J Infect 2006.
7. Mesner O, Riesenberg K, Biliar N, et al. The many faces of human-to-human transmission of brucellosis: congenital infection and outbreak of nosocomial disease related to an unrecognized clinical case. Clin Infect Dis 2007.
8. Mantur BG, Mangalgi SS, Mulimani M. Brucella melitensis--a sexually transmissible agent? Lancet 1996.
9. Wang W, Liao Q, Wu X, et al. Potential risk of blood transfusion-transmitted brucellosis in an endemic area of China. Transfusion 2015.
10. Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007.
11. SPINK WW. What is chronic brucellosis? Ann Intern Med 1951.
12. Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia - 10 years of clinical experience in endemic region. Croat Med J 2010.
13. Doganay M, Aygen B. Human brucellosis: An overview. Int J Infect Dis 2003.
14. Karakukcu M, Patiroglu T, Ozdemir MA, et al. Pancytopenia, a rare hematologic manifestation of brucellosis in children. J Pediatr Hematol Oncol 2004.
15. Sommers H M. The microbiology laboratory in the diagnosis of infectious arthritis. Clin Rhemn Dis 1978.
16. Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985.
17. Julkunen H. Reactive arthritis. Bull Rheum Dis 1979.
18. Andonopoulos AP, Asimakopoulos G, Anastasiou E, Bassaris HP. Brucella arthritis. Scand J Rheumatol 1986.
19. Al-Eissa YA, Kambal AM, Alrabeeah AA, et al. Osteoarticular brucellosis in children. Ann Rheum Dis 1990.
20. Gotuzzo E, Alarcón GS, Bocanegra TS, et al. Articular involvement in human brucellosis: a retrospective analysis of 304 cases. Semin Arthritis Rheum 1982.
21. Erdem H, Kilic S, Sener B, et al. Diagnosis of chronic brucellar meningitis and meningoencephalitis: the results of the Istanbul-2 study. Clin Microbiol Infect 2013.
22. Guven T, Ugurlu K, Ergonul O, et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis 2013.
23. Conkar S, Kosker M, Cevik S, Ay M. Association of brucellosis with renal tubular and glomerular damage in children in Turkey. Saudi J Kidney Dis Transpl 2018.
24. Demiroğlu YZ, Turunç T, Alişkan H, et al. [Brucellosis: retrospective evaluation of the clinical, laboratory and epidemiological features of 151 cases].
25. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007.
26. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995.
27. Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis. Swiss Med Wkly 2004.
28. Solera J, Martínez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997.
29. Al Dahouk S, Tomaso H, Nöckler K, et al. Laboratory-based diagnosis of brucellosis--a review of the literature. Part II: serological tests for brucellosis. Clin Lab 2003.
30. Mantecón Mde L, Gutiérrez MP, Zarzosa Mdel P, et al. Influence of brucellosis history on serological diagnosis and evolution of patients with acute brucellosis. J Infect 2008.
31. Solera J, Martínez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997.
32. WHO Brucellosis in humans and animals Geneva: World Health Organization, 2006.
33. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007.
34. Julkunen H. Reactive arthritis. Bull Rheum Dis 1979.
35. Andonopoulos AP, Asimakopoulos G, Anastasiou E, Bassaris HP. Brucella arthritis. Scand J Rheumatol 1986.

Dr Gopinatha Menon

Senior Coordinator- Department of Internal Medicine, KIMS HEALTH Trivandrum Kerala, India